Director
Christian Rommel, Ph.D.
Christian Rommel, Ph.D., has served on our Board of Directors since May 2024. He is currently the Executive Vice President, Global Head of Research & Development and Member of the Pharmaceuticals Leadership Team at Bayer, a role he has held since February 2021. From January 2014 to February 2021, Dr. Rommel served in various roles at Roche, most recently as Senior Vice President, Global Head of Pharma Research and Early Development (pRED) Oncology. Prior to this, Dr. Rommel worked at Amgen where he held roles including Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech, from its inception to its acquisition by Takeda Pharmaceuticals.
Dr. Rommel also contributes to the Board of Directors for Asklepios Bio., BlueRock Therapeutics, Bayer Radiology, and Vividion Therapeutics. He also serves on the Board of Trustees for the Max Planck Institute for Molecular Genetics.
Dr. Rommel received his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland. In addition to his leadership roles, he lectured biotechnology at the ETH Zurich, Switzerland for several years. He has authored more than 70 publications, including papers in Science and Nature.
